Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. by Volarevic, Vladislav et al.
cells
Article
Galectin-3 Regulates Indoleamine-2,3-dioxygenase-
Dependent Cross-Talk between Colon-Infiltrating
Dendritic Cells and T Regulatory Cells and May
Represent a Valuable Biomarker for Monitoring the
Progression of Ulcerative Colitis
Vladislav Volarevic 1,*, Natasa Zdravkovic 2,3, Carl Randall Harrell 4, Nebojsa Arsenijevic 1,
Crissy Fellabaum 4 , Valentin Djonov 5, Miodrag L. Lukic 1 and Bojana Simovic Markovic 1
1 Department for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research,
Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia
2 Department of Internal medicine, Faculty of Medical Sciences, University of Kragujevac,
69 Svetozar Markovic Street, 34000 Kragujevac, Serbia
3 Center for Gastroenterology, Clinical Center Kragujevac, 30 Zmaj Jovina Stret, 34000 Kragujevac, Serbia
4 Regenerative Processing Plant, LLC, 34176 US Highway 19 N Palm Harbor, Palm Harbor, FL 34684, USA
5 Institute of Anatomy, University of Bern, 2 Baltzerstrasse, 3012 Bern, Switzerland
* Correspondence: drvolarevic@yahoo.com; Tel./Fax: +381-3430-6800
Received: 29 April 2019; Accepted: 3 July 2019; Published: 12 July 2019


Abstract: Galectin-3 regulates numerous biological processes in the gut. We investigated molecular
mechanisms responsible for the Galectin-3-dependent regulation of colon inflammation and evaluated
whether Galectin-3 may be used as biomarker for monitoring the progression of ulcerative colitis
(UC). The differences in disease progression between dextran sodium sulphate-treated wild type and
Galectin-3-deficient mice were investigated and confirmed in clinical settings, in 65 patients suffering
from mild, moderate, and severe colitis. During the induction phase of colitis, Galectin-3 promoted
interleukin-1β-induced polarization of colonic macrophages towards inflammatory phenotype. In the
recovery phase of colitis, Galectin-3 was required for the immunosuppressive function of regulatory
dendritic cells (DCs). Regulatory DCs in Galectin-3:Toll-like receptor-4:Kynurenine-dependent
manner promoted the expansion of colon-infiltrated T regulatory cells (Tregs) and suppressed Th1
and Th17 cell-driven colon inflammation. Concentration of Galectin-3 in serum and stool samples of
UC patients negatively correlated with clinical, endoscopic, and histological parameters of colitis.
The cutoff serum values of Galectin-3 that allowed the discrimination of mild from moderate and
moderate from severe colitis were 954 pg/mL and 580 pg/mL, respectively. Fecal levels of Galectin-3
higher than 553.44 pg/mL indicated attenuation of UC. In summing up, Galectin-3 regulates the
cross-talk between colon-infiltrating DCs and Tregs and represents a new biomarker for monitoring
the progression of UC.
Keywords: ulcerative colitis; Galectin-3; dendritic cells; T regulatory cells; Kynurenine; Toll-like
receptor-4; immunomodulation; biomarker
1. Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) confined to the colon [1].
It is characterized by epithelial cell destruction, connective tissue defects, ulceration of the mucosa and
continuous or discontinuous mucosal inflammation, which results in remitting and relapsing clinical
course [2]. Symptoms are often unspecific and may vary with the disease course making it difficult to
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clinically assess disease activity [3]. Accordingly, the standard of care implies a close monitoring of the
histological and endoscopic parameters of disease severity in order to timely prevent life threatening
aggravation of disease [4]. While endoscopic evaluation of UC progression is the gold standard
for the follow-up of UC patients, this diagnostic approach is invasive and time-consuming [3,4].
Therefore, measurement of non-invasive inflammation-related biomarkes (C-reactive protein (CRP),
fecal calprotectin (FC), and lactoferrin (FL)) in serum and stool samples of UC patients are nowadays
used in clinical practice to defer the need for colonoscopic evaluation [5,6]. Keeping in mind that these
biomarkers have some limitations related to alimentary ingestion, non-steroidal anti-inflammatory
drugs intake and inability of distinguishing inflammation from infection, there is still a need for a
new, non-invasive biomarker, which should complement CRP, FC and FL in determination of UC
progression [7].
Considerable interest has recently arisen in the intriguing immunomodulatory properties
of Galectin 3 (Gal-3), a member of β-galactoside-binding lectins, which regulates numerous
biological processes in the gut including migration, proliferation, and activation of resident and
colon-infiltrated immune cells. Concentration of Gal-3 was significantly increased in serum samples
of UC patients compared to healthy controls [8]. Interestingly, lack of Gal-3 expression showed
different effects on the effector function of colon-infiltrated macrophages and T cells [9–11]. Gal-3
is highly expressed on colonic macrophages of UC patients and its deficiency inhibits activation
of NLRP3 inflammasome and production of inflammatory cytokines in these cells, resulting in
attenuation of acute colitis [9]. On contrary, after the treatment with recombinant Gal-3, T cells of UC
patients developed immunosuppressive phenotype and are not able to optimally proliferate [10–12].
Additionally, adoptive transfer of Gal-3-primed T cells significantly attenuated chronic dextran sodium
sulphate sodium (DSS)-induced colitis in mice [10–12]. Keeping in mind that macrophages play
important roles in the induction phase of colitis, while T cells are the most important effector immune
cells for progression of colon inflammation, herewith, by using clinical data and complementary
in vitro and in vivo approaches, we tried to delineate molecular mechanisms, which are responsible for
Gal-3-dependent regulation of immune response in the inflamed gut and to determine whether Gal-3
may be used as a valuable biomarker for monitoring UC progression. We demonstrated that, during
the induction phase of colitis, Gal-3 promotes interleukin (IL)-1β-induced polarization of colonic
macrophages towards inflammatory M1 phenotype, while in the recovery phase of colitis Gal-3 controls
T cell-driven colon inflammation by down-regulating immunosuppressive function of dendritic cells
(DCs) in the gut. Gal-3 is required for optimal toll-like receptor (TLR)-4-dependent activation of
indoleamine 2,3-dioxygenase-1/kynurenine (IDO-1/KYN) pathway in DCs which promotes expansion
of colon-infiltrated T regulatory cells (Tregs), and therefore, suppresses Th1 and Th17 cell-driven chronic
colitis. Since concentration of Gal-3 in serum and stool samples of UC patients negatively correlated
with clinical, endoscopic, and histological parameters of disease severity, we proposed that Gal-3
might serve as a valuable biomarker for monitoring disease progression. Accordingly, we determined
the precise “cut off” values of serum and fecal Gal-3, which might be used for distinguishing mild,
moderate, and severe forms of UC.
2. Materials and Methods
2.1. Study Population
This study recruited a total of 65 patients with UC (38 male and 27 female) with a median age
of 50 years (range 26–82). Additionally, 30 healthy subjects (16 male and 14 female) with a median
age of 48 years (range 25–75), whose checkups were finished at the Clinical Center of Kragujevac as a
routine item, were randomly chosen to represent the general population as healthy controls. Patients
with UC were classified into three groups: Mild, moderate, and severe colitis. All endoscopies were
performed by the same experienced endoscopist. The exclusion criteria were pregnancy, organ-specific
and systemic acute or chronic inflammatory disorders, autoimmune diseases, severe, and life-treating
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diseases (heart failure, arrythmias, renal insufficiency, respiratory insufficiency, fulminant liver injury),
and malignant disease, including colorectal cancer. Since galectin profiling could not distinguish
Crohn’s disease and UC-related pathological changes in the gut [13], in order to specifically determine
the role of Gal-3 in the pathogenesis of UC, patients with Crohn’s disease were excluded from the
study. The study was conducted at the Center for Gastroenterology, Clinical Center of Kragujevac and
Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of
Kragujevac, Serbia and was approved by the Ethics Committees of these institutions. The Principle
of Good Clinical Practice and the Declaration of Helsinki were adhered to at all times. All patients
gave their informed consent for blood and tissue analysis. Patients were under continuous medical
supervision at the Clinical Center of Kragujevac.
2.2. Measurements of Gal-3, IDO Activity, Concentration of Cytokines, and Fecal Calprotectin in Serum and
Fecal Samples of Patients with UC and Healthy Controls
Blood and fecal samples were prepared as previously described [14]. IDO activity was determined
by spectrophotometric assay for KYN in the serum and fecal samples of patients with UC and healthy
controls [15]. Gal-3, IL-10, C-X-C motif chemokine 11 (CXCL11), IL-17, and fecal calprotectin were
measured in serum and/or fecal samples of UC patients and healthy subjects by using commercially
available enzyme-linked immunosorbent assay (ELISA) kit sets, according to the manufacturer’s
instructions [16].
2.3. Isolation of Colon-Infiltrating Tregs from the Colon Samples of UC Patients and Flow Cytometry Analysis
of Their Phenotype and Function
The phenotype of colon-infiltrating Tregs was determined by flow cytometry [17]. Briefly, about
1 × 106 cells per sample were incubated with antihuman CD4 and IL-10 antibody conjugated with
fluorescein isothiocyanate (FITC; BD Biosciences, Franklin Lakes, NJ, USA), phycoerythrin (PE; BD
Biosciences), peridinin chlorophyll A protein (PerCP; BD Biosciences) or allophycocyanin (APC; BD
Biosciences). For the intracellular staining, cells were previously stimulated with phorbol myristate
acetate (PMA) and ionomycin for 4 h at 37 ◦C with the addition of 1 µg/mL Golgi plug. Intracellular
staining for forkhead box P3 (Foxp3) was performed using the BD Bioscience fixation/permeabilization
buffer kit. Flow cytometric analysis was conducted on a BD Biosciences FACSCalibur and analyzed by
using the flowing software analysis program.
2.4. Cytokine Production in T Cells from UC Patients
T cells (1 × 106 cells per well), isolated from the population of peripheral blood mononuclear cells
of UC patients, were primed with 5 µg/mL Concanavalin A (polyclonal potent activator of T cells) and
cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mmol/L Lglutamine, 1 mmol/L penicillin-streptomycin, and 1 mmol/L mixed nonessential
amino acids (Sigma, Munich, Germany) at 37 ◦C in 5% CO2 in a fully humidified atmosphere for 48 h,
as previously suggested [18]. The levels of transforming growth factor beta (TGF-β), IL-10, IL-17, and
interferon gamma (IFN-γ) were determined in cell culture supernatants by ELISA sets and correlated
with concentrations of Gal-3.
2.5. Animals
All animal experiments were approved by and conducted in accordance with the guidelines of the
Animal Ethics Committee of the Faculty of Medical Sciences, University of Kragujevac, Serbia. Breeding
pairs of Gal-3−/− and WT C57BL/6 mice of the same substrain, initially obtained from Dr. Daniel Hsu
(University of California, Davis, CA, USA), were maintained in animal facilities of the Faculty of
Medical Sciences, University of Kragujevac, Serbia. The total number of 10 mice per experimental
group and 6 mice per control group were used. Mice used for experiments were male and age-matched
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(8 weeks old) and housed with a 12 h light-dark cycle and were administered by standard laboratory
chow and water ad libitum.
2.6. Induction and Evaluation of Colitis in Mice
DSS (2.2%, molecular weight 40 kDa; TdB Consultancy, Uppsala, Sweden) was given to mice in
place of normal drinking water for 5 days ad libitum. After that, DSS was substituted with normal
drinking water for 3 weeks ad libitum [19]. Control mice had access to DSS-free water.
Animal weight loss, stool consistency, and fecal blood were recorded daily for each animal. These
parameters were used to calculate an average Disease Activity Index (DAI) for each animal [20].
For histological analysis, colons were removed from euthanized mice, rinsed with phosphate buffer
solution (PBS), and cut longitudinally before being rolled into ‘Swiss roll’ [21]. Swiss-rolled colons
were fixed in formalin, embedded in paraffin, 5 µm sections were stained with haematoxylin-eosin
(H&E), and examined in a blinded manner by a pathologist. Sections were analyzed for damage to
epithelium, including damage to crypts, submucosal edema, hemorrhage, and infiltration by immune
cells. The histology score for each mouse was calculated as the sum of two parameters (infiltration and
damage of crypts) [22].
2.7. Flow Cytometry Analysis of Colon Infiltrating Immune Cells of DSS-Treated Mice
Isolation of immune cells from lamina propria of DSS-treated mice and flow cytometry analysis
were conducted as previously described [9]. Flow cytometry followed routine procedures by using
1 × 106 cells per sample, which were incubated with anti-mouse F4/80, CD4, CD11c, CD80, CD40,
and CD86 conjugated with FITC, PE, PERCP, or APC (BD Biosciences, Franklin Lakes, NJ). For the
intracellular staining, cells were previously stimulated with PMA and ionomycin for 4 h at 37 ◦C with
the addition of 1 µg/mL Golgi plug. Following extracellular staining, cells were fixed, permeabilised,
and stained for IL-10, Foxp3, IL-17, IFN-γ, IL-12, IL-6, IL-4, TGF-β, and IL-23 conjugated with FITC,
PE, PERCP, or APC (BD Biosciences, Franklin Lakes, NJ). Flow cytometric analysis was conducted on a
BD Biosciences FACSCalibur and analyzed by Flowing Software analysis program.
2.8. Measurements of Cytokines in Serum Samples of DSS-Treated Mice
The commercial ELISA sets (R&D Systems, Minneapolis, MN, USA) were used to determine the
concentration of IL-12, IL-6, IL-17, IFN-γ, tumor necrosis factor alpha (TNF-α), TGF-β, and IL-10 in
serum samples of control and DSS-treated animals [9].
2.9. Isolation and TLR-4-Priming of DCs
DCs were isolated from spleens of 10 WT and Gal-3−/− mice by magnetic cell sorting. Single-cell
suspensions of mononuclear cells were labelled with CD11c MicroBeads (Miltenyi Biotec, Bergisch
Gladbach, Germany). The labelled cells were subsequently positively selected using MACS Column
(Miltenyi Biotec) and MACS Separator (Miltenyi Biotec) [23]. Isolated DCs (3 × 105/mL) were primed
with Lipopolysaccharide (LPS, 10 ng/mL) for 48 h [24].
2.10. Pharmacological Inhibition of Gal-3 in DCs
Pharmacological inhibition of Gal-3 in DCs was induced by selective Gal-3 inhibitors. WT DCs
were cultured in the presence of Davanat (DCsDavanat 15 µg/mL) for 24 h, according to previously
published protocol [25].
2.11. Determination of IDO1 Activity
IDO1 activity in serums samples as well as in supernatants of TLR-4-primed WTDCs, Gal-3−/−DCs
and DCsDavanat was determined by spectrophotometric measuring of KYN [14,23].
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2.12. Adoptive Transfer of TLR-4 Primed DCs in DSS-Treated Mice
For adoptive transfer experiments, TLR-4 primed WT and Gal-3−/− animals, were transferred
(intraperitoneally; 2 × 105 DCs/mouse) into DSS-treated WT recipients on the 5th and 15th day [26,27].
2.13. Co-culture of TLR-4-Primed DCs and Tregs
Tregs were isolated from the population of spleen mononuclear cells obtained from 10 WT mice
by magnetic cell sorting (Tregs isolation kit, Miltenyi Biotec, Bergisch Gladbach, Germany) [28] and
co-cultured in the presence of TLR-4-primed WTDCs, Gal-3−/−DCs, or WTDCsDavanat [29]. After 48h
of culture, Tregs were collected for co-culture experiments with T cells and frozen at −80 ◦C until gene
expressions were measured by real-time PCR.
2.14. Co-Culture of Tregs and Effector T Cells
Tregs, previously cultured in the presence of TLR-4 primed WTDCs, Gal-3−/−DCs, or WTDCsDavanat
were co-cultured with Con-A primed T cells. After 48 h, the expression of IFN-γ, IL-17, and IL-10 in
activated T cells was evaluated by real time PCR analysis.
2.15. RNA Isolation and Real-Time PCR Analysis
Total RNA from T cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total
RNA (2 µg) was reverse transcribed to cDNA using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). qRT-PCR was performed using Power SYBR MasterMix
(Applied Biosystems) and miRNA-specific primers for IFN-γ, IL-17, IL-10, andβ-actin as a housekeeping
gene. qPCR reactions were initiated with a 10-min incubation time at 95 ◦C followed by 40 cycles
of 95 ◦C for 15 s and 60 ◦C for 60 s in a Mastercycler ep realplex (Eppendorf, Hamburg, Germany).
Relative expression of genes was calculated according to the formula 2-(Ct-Ctactin), where Ct is the
cycle threshold of the gene of interest and Ctactin is the cycle threshold value of the housekeeping
gene (β-actin) [30].
2.16. Statistics
Data were expressed as the mean ± standard error of the mean (SEM) for each group. Results
were analysed by Student’s t test and Pearson’s or Spearman’s correlation coefficient. Fisher’s exact
test was used to assess survival differences between groups. A receiver operated characteristic (ROC)
curve was generated by plotting the false positive fraction versus the true-positive fraction for every
possible cutoff score. Statistical analyses were performed using SPSS 25.0 for Windows software (SPSS
Inc., Chicago, IL, USA). The difference was considered significant when p < 0.05.
3. Results
3.1. Gal-3 Had Pro-Inflammatory Role in Induction Phase of Colitis, but Its Deficiency Significantly Impaired
Recovery from DSS-Induced Colon Injury
In order to determine which molecular and cellular mechanisms were responsible for Gal-3-
dependent regulation of immune response during inductive and recovery phases of colitis, we compared
the differences in clinical course, survival rate, and colon architecture between WT and Gal-3−/− mice
during the development and progression of acute DSS-induced colitis. DSS-treated WT animals start
to lose their weight few days before Gal-3−/− mice (at day 3) and body weight loss was significantly
lower in DSS-treated WT animals compared to Gal-3−/− mice at day 5 (Figure 1A). WT and Gal-3−/−
mice continued to lose body weight after DSS removal. Seven days upon DSS withdrawal (at day 12),
WT mice started to recover their weight, reaching their original weight at day 28. On the contrary,
Gal-3−/− mice continuously lose their weight resulting in significantly higher weight loss compared to
their WT counterparts at day 28 (Figure 1A).
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of weight (A); Disease Activity Index DAI (B); and survival rate (C) 5 days after colitis induction. 
Length of colon (D) and histological score (E) of DSS-treated mice. Haematoxylin and eosin (H&E) 
stained colon tissue samples of DSS-treated mice (magnification 100×) (F). Concentrations of IL-1β, 
TNF-α, IL-6 (G), IL-10 (H), IFN-γ (I), IL-17 (J), and KYN (K) in serum samples of DSS-treated mice at 
day 5. The total number M1 and M2 macrophages in colons of DSS-treated animals (L). Data are 
presented as mean ± standard error of the mean (SEM); n = 10 mice per experimental and 6 mice per 
control groups. *p < 0.05, **p < 0.001. 
During the inductive phase of acute colitis, clinical signs were more severe in WT animals 
(Figure 1B), while more aggravated disease was observed in DSS-treated Gal-3−/− mice during the 
progression of the disease (Figure 2A). Fecal blood was detected in WT animals at day 2, whereas 
gross rectal bleeding and diarrhea were observed from day 4. These signs of colon injury started to 
appear in Gal-3−/− mice from day 5. Visible blood in stool samples of DSS-treated WT mice could not 
be detected after day 16, and from day 12, the stool loss was not as prominent as during the induction 
phase of colitis. On the contrary, massive rectal bleeding and watery diarrhea were continuously 
observed in DSS-treated Gal-3−/− mice until the end of experiment. Accordingly, DAI score was 
Figure 1. Gal-3 has pro-inflammatory role in induction phase of DSS-induced colitis. 2.2% DSS was
given to mice for 5 days while regular drinking water was given to control animals. DSS-induced
loss of weight (A); Disease Activity Index DAI (B); and survival rate (C) 5 days after colitis induction.
Length of colon (D) and histological score (E) of DSS-treated mice. Haematoxylin and eosin (H&E)
stained colon tissue samples of DSS-treated mice (magnification 100×) (F). Concentrations of IL-1β,
TNF-α, IL-6 (G), IL-10 (H), IFN-γ (I), IL-17 (J), and KYN (K) in serum samples of DSS-treated mice
at day 5. The total number M1 and M2 macrophages in colons of DSS-treated animals (L). Data are
presented as mean ± standard error of the mean (SEM); n = 10 mice per experimental and 6 mice per
control groups. * p < 0.05, ** p < 0.001.
During the inductive phase of acute colitis, clinical signs were more severe in WT animals
(Figure 1B), while more aggravated disease was observed in DSS-treated Gal-3−/− mice during the
progression of the disease (Figure 2A). Fecal blood was detected in WT animals at day 2, whereas gross
rectal bleeding and diarrhea were observed from day 4. These signs of colon injury started to appear in
Gal-3−/− mice from day 5. Visible blood in stool samples of DSS-treated WT mice could not be detected
after day 16, and from day 12, the stool loss was not as prominent as during the induction phase of
colitis. On the contrary, massive rectal bleeding and watery diarrhea were continuously observed
in DSS-treated Gal-3−/− mice until the end of experiment. Accordingly, DAI score was significantly
lower in DSS-treated Gal-3−/− mice at the end of induction phase of colitis (day 5, Figure 1B), but was
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significantly higher at day 28 (Figure 2A). In line with these findings, Gal-3 deficiency improved
survival (Figure 1C) and significantly increased length of colon of DSS-treated mice (p < 0.05; Figure 1D)
at the end of induction phase of colitis. On the contrary, remarkably reduced survival rate (Figure 2B)
and significantly increased colonic shortening (p < 0.01, Figure 2C) were observed in Gal-3−/− mice at
day 28.
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Figure 2. Gal-3 deficiency significantly aggravated colon injury and inflammation in chronic phase of 
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(F), IL-10 (G), KYN (H), and total number of colon-infiltrated M1 and M2 macrophages (I) in DSS-
treated WT and Gal-3−/− mice, 28 days after initial DSS administration. Values are mean ± standard 
Figure 2. Gal-3 deficiency significantly aggravated colon injury and inflammation in chronic phase of
DSS-induced colitis. DAI (A), survival rate (B), length of colon (C), histological score (D), representative
H&E stained colon tissue samples (E), serum concentration of IL-6, IL-12, IL-17, IFN-γ (F), IL-10 (G),
KYN (H), and total number of colon-infiltrated M1 and M2 macrophages (I) in DSS-treated WT and
Gal-3−/− mice, 28 days after initial DSS administration. Values are mean ± standard error of the mean
(SEM) (n = 10 mice per experimental and 6 mice per control groups) * p < 0.05, ** p < 0.001.
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In line with these findings were the results obtained by histological analysis (Figure 1E–F and
Figure 2D–E). Histological score was significantly lower in DSS-treated Gal-3−/− mice at the end of
induction phase of colitis (p < 0.01, Figure 1E). Histological analysis revealed that 5 days of DSS
treatment caused significant epithelial cell damage, edema, ulceration, and extensive crypt drop-out
in colons of WT mice (Figure 1Fb), while only mild evidence of crypt distortion and widening were
observed in colon samples of Gal-3−/− animals (Figure 1Fd). Opposite findings were observed at day
28 resulting in significantly higher histological score in DSS-treated Gal-3−/− mice (p < 0.05; Figure 2D).
Histological analyses showed that DSS-caused pathological changes (loss of intestinal epithelial cells,
decreased number of crypts, and submucosal edema) were still present in the colons of WT mice,
4 weeks after initial administration of DSS (Figure 2Eb). Importantly, all of these abnormalities in colon
architecture were more prominent in Gal-3−/− mice (Figure 2Ed). Destruction of the entire epithelium,
more prominent loss of crypts and goblet cells, accompanied with more severe submucosal edema and
massive accumulation of lymphocytes were observed in the colons of DSS-treated Gal-3−/− mice at day
28 (Figure 2Fd).
Genetic deletion of Gal-3 affected cytokine networking of innate immune cells in the induction
phase of colitis (Figure 1G,H) and altered cytokine release from adaptive immune cells during the
progression of DSS-induced colitis (Figure 2F–H). Significantly lower concentrations of inflammatory
cytokines of innate immunity (p < 0.05 for IL-1β, TNF-α, and IL-6) were observed in serum samples
of DSS-treated Gal-3−/− mice at the end of induction phase of colitis (Figure 1G). Additionally, Gal-3
deficient mice had elevated serum levels of anti-inflammatory IL-10 (p < 0.01; Figure 1H), while there
was no significant difference in serum levels of inflammatory, T cell-derived cytokines (IFN-γ and IL-17;
Figure 1I,J) and immunosuppressive KYN (Figure 1K) between DSS-treated WT and Gal-3−/− mice
at day 5. On the contrary, serum levels of immunosuppressive IL-10 (p < 0.05; Figure 2G) and KYN
(p < 0.05; Figure 2H) were significantly lower, while concentration of inflammatory Th1 cell-derived
IFN-γ Th17 cell-derived IL-17 were significantly higher (p < 0.05; Figure 2F) in serum samples of
DSS-treated Gal-3−/− mice at day 28.
Macrophages orchestrate the cross-talk between colon-infiltrating immune cells in induction
phase of acute DSS- colitis [31,32]. Cellular make-up of the DSS-injured colons revealed significantly
lower number of inflammatory, IL-1β- (p < 0.05), TNF-α-( p <0.05), IL-6 (p < 0.05), and IL-12-producing
M1 macrophages (p < 0.01), but a significantly higher number of IL-10-, IL-4, and TGF-β-producing
M2 macrophages (p < 0.05) in the colons of DSS-treated Gal-3−/− mice at day 5 (Figure 1L). On the
contrary, total number of IL-10-, IL-4 and TGF-β-producing M2 macrophages was remarkably lower
(p < 0.05) and total number of IL-12-producing M1 macrophages (p < 0.05) was significantly higher in
the colons of DSS-treated Gal-3−/− mice 28 days after the initial administration of DSS (Figure 2I).
3.2. Gal-3 Deficiency Resulted in Enhanced DC-Dependent Activation of Inflammatory Th1 and Th17 Cells in
DSS-Induced Colitis
T cells have crucially important role in the progression of DSS-induced colon inflammation [33].
Accordingly, significantly higher number of CD4+ T cells was seen in colons of Gal-3−/− mice 28 days
after initial administration of DSS (p < 0.01; Figure 3A). Intracellular staining revealed significantly
higher presence of colon-infiltrating, IFN-γ producing CD4+ Th1 cells (p < 0.01; Figure 3B) and
IL-17-producing CD4+Th17 cells (p < 0.05; Figure 3C) in DSS-treated Gal-3−/− mice. In contrast,
significantly lower presence of immunosuppressive, IL-10-producing CD4+T cells (p < 0.05; Figure 3D)
and FoxP3+CD4+Tregs (p < 0.05, Figure 3E) were observed in colons of DSS-treated Gal-3−/−
mice, suggesting that Gal-3 deficiency altered the polarization of colon-infiltrated T cells towards
pro-inflammatory Th1/Th17 phenotype.
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Th17 cells ( ), erce tage of reg latory cells (CD4+I -10 a 4 Fox 3 IL-10+) (D,E) with
representative flo cyto etry dot plots are presented. Values are ean ± standard error of the mean
(SE ) (n = 10 mice per experimental and 6 mice per control groups). * p < 0.05, ** p < 0.001.
Since DCs regulate progression of DSS-induced colitis by inducing polarization of CD4+T cells in
inflammatory (Th1/Th17) or immunosuppressive (Tregs) cells [17,23], we analyzed whether genetic
deletion of Gal-3 affected phenotype and function of colon-infiltrating DCs 28 days after the initial
administration of DSS. Firstly, we observed a significantly higher number of CD11c+DCs in the colons
of DSS-treated Gal-3−/− mice (Figure 4A). Additionally, a remarkably higher number of CD40−(p < 0.05;
Figure 4B), CD80−(p < 0.05; Figure 4C), and CD86−(p < 0.01; Figure 4D) expressing DCs were seen in the
colons of DSS-treated Gal-3−/− mice, suggesting that significantly increased number of activated DCs
with potent antigen presenting function infiltrated DSS-injured colons of Gal-3−/− animals. Intracellular
staining revealed that IL-12-producing DCs (p < 0.05, Figure 4E), which induced generation of Th1
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cells [16], as well as IL-23 and IL-6-producing DCs (p < 0.05, Figure 4F,G), which promoted generation
of Th17 cells [17,23], were present in significantly higher number in colons of DSS-treated Gal-3−/−
mice. In contrast, significantly lower number of regulatory, IL-10-producing DCs (p < 0.05; Figure 4H),
which suppressed T cell-driven colon inflammation [16], was observed in Gal-3−/− animals 28 days
after initial DSS administration.
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The total number of CD11c+ DCs in colons of DSS-treated WT and Gal-3−/− mice 28 days after initial
DSS administration (A). The total number of CD40, CD80 and CD86-expressing CD11c+DCs (B–D)
and IL-12, IL-23, IL-6, and IL-10 producing CD11c+DCs in colons of DSS-treated WT and Gal-3−/− mice
(E–H). Data are presented as mean ± standard error of the mean (SEM); n = 10 mice per experimental
and 6 mice per control groups. * p < 0.05, ** p < 0.001.
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3.3. Gal-3 is Required for Optimal TLR-4-Dependent Production of KYN in DCs
It is well known that LPS priming induces activation of IDO-1/KYN pathway in DCs [34] and that
DCs promote expansion of colon-infiltrating Tregs in IDO-1/KYN-dependent manner [35]. Since we
noticed strong positive correlation between expression of TLR-4 and Gal-3 on colon-infiltrated DCs
of DSS-treated animals (Figure 5A, r = 0.800, p = 0.005), we evaluated the importance of Gal-3 for
TLR-4-dependent activation of IDO-1/KYN pathway in DCs. As it is shown in Figure 5B, activation of
TLR-4 significantly enhanced production of immunosuppressive KYN in WT DCs (Figure 5B; p < 0.01).
Importantly, genetic deletion as well as pharmacological inhibition of Gal-3, remarkably reduced
TLR-4-dependent secretion of KYN in DCs (Figure 5B; p < 0.01). Significantly lower concentrations
of KYN were measured in supernatants of Gal-3−/− DCsLPS and WT DCsLPS+Davanat compared to WT
DCsLPS (Figure 5B, p < 0.01).
Cells 2019, 8, x 11 of 24 
 
3.3. Gal-3 is Required for Optimal TLR-4-Dependent Production of KYN in DCs 
It is well known that LPS priming induces activati n of IDO-1/KYN pathway in DCs [34] and 
that DCs promote expansion of colon-inf ltratin  Tregs in IDO-1/KYN-dependent manner [35]. Since 
we noticed strong positive correlation b tween expression of TLR-4 and Gal-3  colon-infiltrated 
DCs of DSS-tre ted nimals (Figure 5A, r = 0.800, p = .005), we evaluated the importance of Gal-3 for 
TLR-4-dependent activation of IDO-1/KYN pathway in DCs. As it is show  in Figure 5B, activati n 
of TLR-4 significantly e hanced production of imm nosuppressive KYN in WT DCs (Figure 5B; p < 
0.01). Importantly, gen c deletion  well as pharmacological inhibition of Gal-3, remarkably 
reduced TLR-4-depende t secretio  of KYN in DCs (Figure 5B; p < 0.01). Significantly lower 
concentrations of KYN were me sured in supernatants of Gal-3−/− DCsLPS and WT DCsLPS+Davanat 
compared to WT DCsLPS (Figure 5B, p < 0.01). 
 
Figure 5. Gal-3 is required for optimal TLR-4-dependent production of KYN in DCs. Correlation 
between expression of Gal-3 and TLR-4 on colon-infiltrated CD11c+DCs 28 days after initial DSS 
administration (A). KYN production in LPS-primed DCs (B). Expression of IL-10, IFN-γ and IL-17 in 
Tregs which were co-cultured with LPS-primed WTDCs, Gal-3−/−DCs or WTDCDavanat (C–E). 
Expression of IL-10, IFN-γ and IL-17 in activated T cells which were co-cultured with Tregs primed 
by LPS-stimulated WTDCs, Gal-3−/−DCs, or WTDCDavanat (F–H). Data presented as mean ± standard 
error of the mean (SEM); n = 10 mice per experimental groups. **p < 0.001. 
3.4. Gal-3 Deficiency Completely Abrogated Capacity of TLR-4 Primed DCs to Maintain 
Immunosuppressive Function of Tregs 
Genetic deletion as well as pharmacological inhibition of Gal-3 in WT DCsLPS diminished their 
capacity to maintain immunosuppressive phenotype of Tregs (Figure 5C) and to prevent their trans-
differentiation in inflammatory Th1 or Th17 cells (Figure 5D,E). Decreased expression of anti-
inflammatory IL-10 (Figure 5C; p < 0.01) and increased expression of inflammatory IFN-γ (Figure 5D; 
p < 0.01) and IL-17 (Figure 5E; p < 0.01) were noticed in Tregs, which had been cultured with Gal-3−/− 
DCsLPS or WT DCsLPS+Davanat compared to Tregs that were cultured with WT DCsLPS. 
Additionally, Tregs generated by Gal-3−/− DCsLPS or WT DCsLPS+Davanat were not able to optimally 
suppress production of IFN-γ (Figure 5F; p < 0.01) and IL-17 (Figure 5G; p < 0.01) in activated CD4+ 
Figure 5. Gal-3 is required for optimal TLR-4-dependent production of KYN in DCs. Correlation
between expression of Gal-3 and TLR-4 on colon-infiltrated CD11c+DCs 28 days after initial DSS
administration (A). KYN production in LPS-primed DCs (B). Expression of IL-10, IFN-γ and IL-17
in Tregs which were co-cultured with LPS-primed WTDCs, Gal-3−/−DCs or WTDCDavanat (C–E).
Expression of IL-10, IFN-γ and IL-17 in activated T cells which were co-cultured with Tregs primed
by LPS-stimulated WTDCs, Gal-3−/−DCs, or WTDCDavanat (F–H). Data presented as mean ± standard
error of the mean (SEM); n = 10 mice per experimental groups. ** p < 0.001.
3.4. Gal-3 Deficiency Completely Abrogated Capacity of TLR-4 Primed DCs to Maintain Immunosuppressive
Function of Tregs
Genetic deletion as well as pharmacological inhibition of Gal-3 in WT DCsLPS diminished
their capacity to maintain immunosuppressive phenotype of Tregs (Figure 5C) and to prevent
their tra s-differ ntiation in inflammatory Th1 or Th17 cells (Figure 5D,E). Decreased expression
of anti-infla ma ory IL-10 (Figure 5C; p < 0.01) and increased expression of inflammatory IFN-γ
(F gu 5D; p < 0.01) and IL-17 (Figure 5E; p < 0.01) were noticed in Tregs, which had been cultured
with Gal-3−/− DCsLPS or WT DCsLPS+Davanat comp r to T g that were cultured with WT DCsLPS.
Additionally, Tregs generated by Gal-3−/− DCsLPS or WT DCsLPS+Davanat were not able to optimally
suppress production of IFN-γ (Figure 5F; p < 0.01) and IL-17 (Figure 5G; p < 0.01) in activated CD4+
T cells, indicating the importance of Gal-3 for DC-driven regulation of cross-talk between Tregs and
effector T cells.
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3.5. Genetic Deletion of Gal-3 Diminished Capacity of TLR-4-Primed DCs to Attenuate DSS-Induced Colitis
In order to demonstrate crucial role of Gal-3 for DCsLPS-dependent expansion of Tregs and
consequent attenuation of DSS-induced colitis, we injected WT DCsLPS or Gal-3−/− DCsLPS in
DSS-treated mice. Transfer of WT DCsLPS promoted recovery from DSS-induced colitis (Figure 6A–D).
Significantly lower DAI score (p < 0.05; Figure 6A) (evidenced by improved stool consistency and
diminished rectal bleeding), increased colon length (p < 0.05; Figure 6B) and reduced histology score
(p < 0.05; Figure 6C) were observed in DSS-treated mice that received WT DCsLPS. Histological analysis
of their colon sections revealed reduced number of mucosal erosions and ulcerations, lower hyperplasia,
and decreased infiltration of lymphocytes (Figure 6Dc). Importantly, adoptive transfer of WT DCsLPS
significantly increased serum level of KYN in DSS-treated mice (p < 0.001; Figure 6E), which resulted
in the expansion of colon-infiltrating IL-10-producing Tregs (p < 0.05; Figure 6F) and elevated serum
level of IL-10 (p < 0.01; Figure 6G). On contrast, significantly lower number of IFN-γ-producing, T-bet
and CXCR3-expressing Th1 cells (p < 0.01; Figure 6H,I), and IL-17-producing and CCR6-expressing
Th17 cells (p < 0.01; Figure 6J,K), accompanied by significantly reduced serum levels of IFN-γ and
IL-17 (p < 0.05; Figure 6L), were observed in DSS-treated mice after adoptive transfer of WT DCsLPS,
indicating that WT DCsLPS alleviated DSS-induced colitis by suppressing Th1 and Th17 cell-driven
inflammatory response in the gut.
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Figure 6. Genetic deletion of Gal-3 diminished capacity of TLR-4-primed DCs for attenuation of chronic
colitis. DAI (A), length of colon (B), histological score (C), representative H&E ( ), serum levels of KYN
(E) and IL-10 (G), total number of colon-infiltrated immunosuppressive CD4+Foxp3+IL-10+ Tregs
(F), serum level of IL-10 (G), total number of colon-infiltrated inflammatory CD4+T-bet+IFN-γ+Th1
cells (H), CD4+CXCR3+Th1 cells (I), CD4+IL-17+Th17 cells (J) and CD4+CCR6+Th17 cells (K), serum
concentration of IFN-γ and IL-17 (L), and 28 days after adoptive transfer of LPS-primed WTDCs or
Gal-3−/−DCs in DSS-treated mice. Valu s are mean ± standard error of the mean (SEM) (n = 10 mice
per experimental groups and 6 mice per control group). * p < 0.05, ** p < 0.01; *** p < 0.001.
Importantly, the adoptive transfer of Gal-3−/− DCsLPS did not alter serum level of KYN and total
number of colon-infiltrating Tregs in DSS-treated mice (Figure 6E,F), suggesting that Gal-3 was required
for the optimal production of KYN in TLR-4-primed DCs and for consequent Treg-based alleviation of
Th1/Th17 cell-driven colitis.
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3.6. Serum Gal-3 May Serve as A Valuable Marker for Monitoring the Progression of UC
In order to investigate the relevance of experimental findings for corresponding human pathology,
we analyzed the concentration of Gal-3 in serum samples of healthy controls and in patients with UC
who were divided into three groups based on the disease severity (UC patients with mild, moderate
and severe colitis) (Table 1). The serum level of Gal-3 was higher in UC patients compared with
healthy controls (Figure 7A). Interestingly, a significantly higher serum levels of Gal-3 were observed
in patients with mild UC than in patients with moderate UC and in patients with moderate UC than
in patients with severe UC (p < 0.01; Figure 7A). The clinical score negatively correlated with serum
concentrations of Gal-3 (r = −0.667, p < 0.0005; Figure 7C). These findings were in line with differences
in histological (p < 0.001; Figure 7D) and endoscopic scores (p < 0.001; Figure 7E) between these three
groups of UC. In line with these results, serum levels of Gal-3 negatively correlated with histological
score (r = −0.317, p < 0.01; Figure 7F left panel) and with endoscopic subscore (r = −0.256, p < 0.05;
Figure 7F right panel).
Table 1. Demographic and clinical characteristics of UC patients.
Characteristic Mild Chronic
Colitis
Moderate
Chronic Colitis
Severe Chronic
Colitis
Number of patients 39 18 8
Age (range) 26–74 29–82 30–73
Disease location
Proctitis/left sided-distal UC/pancolitis
10/23/6 1/10/7 0/4/4
Hb, median (IQR) 134 (8) 109 (18.25) 110.5 (13)
Fe, median (IQR) 14.5 (6.10) 8.15 (6.93) 6.5 (4.4)
Ferritin, median (IQR) 239 (109) 53.5 (102) 20.5 (65.75)
Platelets, median (IQR) 392 (110) 457.5 (124.25) 491.5 (138.25)
UIBC, median (IQR) 44 (13) 32.5 (16.25) 32 (21.5)
TIBC, median (IQR) 52 (12) 56.5 (12.5) 53 (23)
CEA, median (IQR) 1.8 (1.95) 3.75 (2.32) 4.1 (9.59)
CA 19-9, median (IQR) 2.9 (2.4) 10.58 (12.62) 17.82 (21.1)
Disease duration (months) (median; range) 4.4 (1.5–16.5) 6,2 (2.7–10.9) 16.5 (11.4–17.9)
Current therapy
AS/CS/IS/IS+BT/BT
38/0/1/0/0 4/0/10/2/2 0/0/4/2/2
Former therapies
AS/CS/IS/IS+BT/BT
34/5/0/0/0 2/14/0/1/1 0/6/0/0/2
Per oral steroids at diagnosis Yes/No 5/34 14/4 6/2
Other diseases
(Glaucoma/Gonarthrosis)
1/0/ 1/1 1/0
Other medications
(PG Eye drops/HA)
1/0 1/1 1/0
Smoking status
Yes/No
3/36 2/16 0/8
Abbreviations: UC- ulcerative colitis; N- Number; IQR- interquartile range; Hb- hemoglobin; Fe- iron;
UIBC-transferrin and iron binding capacity; UIBC-unsaturated iron binding capacity; AS- Aminosalicylates
(5-aminosalicylic acid, or 5-ASA); CS- Corticosteroids; IS- Immunosuppressives; BT- Biological therapy (anti-TNF-α
monoclonal antibody); PG Eye drops-Prostaglandin Eye drops; HA- Hyaluronic Acid (intra-articular injection).
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ser m levels of Gal-3 (A), clinical score (B), histological score (D), endoscopic sc re (E) i UC patients
with mild, m derate or severe forms of UC. C rrelation between clini al s ore and serum levels of
Gal-3 (C). Representative histological sections (D, magnification of 200×) and endoscopic imag s (E)
of UC patients with mild, moderate, or severe forms of UC. (D). Correlatio between serum lev ls of
Gal-3 and histological or endoscopic score (F). ROC curve illustrate the specificity and sensiti ity f
al-3 serum concentration, comparing mild chronic colitis with moderate chronic colitis (left panel)
and specificity and sensitivity of sera Gal-3, comparing moderate chronic colitis with severe chronic
colitis (right panel) (G). Mean ± standard error of the mean; ** p < 0.01; *** p < 0.001.
ROC analysis was performed to evaluate the usefulness of serum Gal-3 levels for classification of
UC patients with mild, moderate or severe colitis. ROC analysis showed that serum Gal-3 can be used
a valuable marker for monitoring UC progression (sensitivity 95%, specificity 91.7%; Figure 7G). The
cutoff serum values of Gal-3 that allowed the discrimination of mild from moderate and moderate
from severe UC were 954pg/mL and 580pg/mL, respectively.
3.7. Increased Serum Levels of Gal-3 Indicates Overproduction of Immunosuppressive Cytokine in UC Patients
Se um concentration of Gal-3 was in a strong positive correlation with serum l vels of KYN
(r = 0.821, p < 0.0005; Figure 8A). Since KYN is mainly responsible for expansion of immunosuppressive
Tregs [16], there was a strong positive correlation between percentage of colon-infiltrating Tregs and
serum level of KYN (r = 0.762, p < 0.0005; Figure 8B) in UC patients. Importantly, serum levels of Gal-3
positively correlated with the percentage of colon-infiltrating Tregs (r = 0.620, p < 0.0005, Figure 8C)
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and with the serum levels of immunosuppressive IL-10 (r = 0.251, p = 0.033, Figure 8D) in UC patients.
In line with these findings, there was strong positive correlation between serum concentration of
Gal-3 and capacity of pbMNCs to produce immunosuppressive cytokines (IL-10 (r = 0.950, p < 0.0005,
Figure 8E) and TGF-β (r = 0.918, p < 0.0005, Figure 8F)). In contrast, there was a negative correlation
between serum levels of Gal-3 and inflammatory Th1-related chemokine CXCL11 (r = –0.229, p = 0.042,
Figure 8G) and IL-17 (r = –0.221, p = 0.046, Figure 8H). In an analogy, serum concentration of Gal-3
negatively correlated with the capacity of pbMNCs to produce IFN-γ (r = –0.864, p < 0.0005, Figure 8I)
and IL-17 (r = –0.482, p = 0.001, Figure 8J).
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3.8. Measurement of Fecal Gal-3 May Be Used for Assessing Severity of UC 
In a similar manner that was observed in serum samples (Figure 7), the concentration of Gal-3 
in stool samples of UC patients was remarkably higher than in healthy controls (Figure 9A). 
Importantly, fecal level of Gal-3 was significantly higher in patients with mild UC than in patients 
with moderate UC and severe UC (p < 0.05; Figure 9A) and it negatively correlated with disease 
progression (r = −0.294, p = 0.049, Figure 9B). Importantly, we noticed negative correlation between 
fecal levels of Gal-3 and concentration of FC (r = −0.250, p = 0.047, Figure 9C), used as a reliable 
biomarker in assessing disease progression in UC patients [36–38]. ROC analysis revealed that, in 
addition to FC, fecal Gal-3 might also be used as a biomarker for monitoring severity of UC (Figure 
Figure 8. Increased serum levels of Gal-3 indicates overproduction of immunosuppressive cytokines in
UC patients. Correlation between serum concentrations of Gal-3 and KYN (A), KYN and percentage of
colon-infiltrated Tregs (B), serum levels of Gal-3 and percentage of colon-infiltrated Tregs (C), serum
concentration of Gal-3 and IL-10 (D). Correlation between serum level of Gal-3 and concentration of
IL-10 (E) and TGF-β (F) in supernatants of Con A-stimulated pbMNCs. Correlation between serum
levels of Gal-3 and CXCL11 (G) and between serum concentration of Gal-3 and IL-17 (H). Correlation
between seru level of Gal-3 and concentration of IFN-γ (I) and IL-17 (J) in supernatants of Con
A-stimulated pbMNCs.
3.8. Measurement of Fecal Gal-3 May Be Used for Assessing Severity of UC
In similar manner th t was obs rve in serum samples (Figure 7), the concentration of Gal-3 in
stool samples of UC patients was remarkably higher than in healthy controls (Figure 9A). Importantly,
fecal level of Gal-3 was significantly higher in patients with mild UC than in patients with moderate
UC and severe UC (p < 0.05; Figure 9A) and it negatively correlated with disease progression (r =
−0.294, p = 0.049, Figure 9B). Importantly, we noticed negative correlation between fecal levels of Gal-3
and concentration of FC (r = −0.250, p = 0.047, Figure 9C), used as a reliable biomarker in assessing
disease progression in UC patients [36–38]. ROC analysis revealed that, in addition to FC, fecal Gal-3
might also be used as a biomarker for monitoring severity of UC (Figure 9D). Concentration of fecal
Gal-3 higher than 553.44 pg/mL indicates attenuation of UC with sensitivity of 72.7% and specificity
60.9%.
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In a similar manner that was observed in serum samples (Figure 7), an increased fecal level of 
Gal-3 indicates overproduction of immunosuppressive cytokines. There was strong positive 
correlation between fecal levels of Gal-3 and fecal concentration of immunosuppressive KYN (r = 
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In a similar manner that was observed in serum samples (Figure 7), an increased fecal level
of Gal-3 indicates overproduction of immunosuppressive cytokines. There was strong positive
correlation between fecal levels of Gal-3 and fecal concentration of immunosuppressive KYN (r = 0.975,
p < 0.0005, Figure 9E). An increased fecal level of Gal-3 also correlated with a higher presence of
immunosuppressive colon-infiltrating Tregs (r = 0.478, p < 0.0005, Figure 9F) and with elevated
concentration of anti-inflammatory IL-10 in stool samples (r = 0.636, p < 0.0005, Figure 9G). In line with
these findings, there was positive correlation between fecal levels of Gal-3 and capacity of pbMNCs to
produce immunosuppressive cytokines (IL-10 (r = 0.344, p = 0.015, Figure 9H) and TGF-β (r = 0.343, p =
0.015, Figure 9I)). On the contrary, fecal Gal-3 negatively correlated with fecal levels of Th1/Th17-related
inflammatory mediators (CXCL11 (r = −0.399, p = 0.003, Figure 9J) and IL-17 ((r = −0.399, p < 0.0005,
Figure 9K)) and with a capacity of pbMNCs to produce IFN-γ (r = −0.420, p = 0.004, Figure 9L) and
IL-17 (r = −0.343, p = 0.015, Figure 9M).
4. Discussion
Herewith, by using an experimental model of DSS-induced colitis and clinical data, we demonstrated
important protective role of Gal-3 in attenuation of UC. Our results indicated that Gal-3 is required
for TLR-4-dependent activation of IDO-1/KYN pathway in colon-infiltrating DCs and for consequent
Tregs-based suppression of Th1/Th17 cell-driven colon inflammation. Furthermore, we proposed
that the measurement of serum and fecal levels of Gal-3 in UC patients might represent a valuable
diagnostic tool for monitoring disease progression.
Different subpopulations of immune cells play distinct roles in the induction and progression of
DSS-induced colitis [32]. Macrophages play crucially important role in the acute phase of DSS-induced
colitis while T cells orchestrate colon-infiltrated immune cells during the progression of DSS-caused
colon inflammation [31,32]. During the onset of DSS-induced colitis, CD14/TLR4:LPS-dependent
interaction between macrophages and bacteria, which have passed through DSS-injured colonic
epithelium, results in the activation of NLRP3 inflammasome, which leads to the enhanced production
of IL-1β in colonic macrophages [39]. Several lines of evidence suggested that IL-1β-dependent
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activation of IL-1 receptor (IL-1R) in gut-infiltrating immune cells have crucially important role
in the development of colon inflammation during the onset of DSS-induced colitis [40–44]. When
LPS-activated, inflammatory M1 macrophages produce large amounts of IL-1β, it binds to IL-1R
and induces increased secretion of pro-inflammatory cytokines (TNF-α, IL-6, IL-12, and IL-18) and
chemokines (CXCL11 and CCL20) in neighboring macrophages, neutrophils and DCs resulting in
the enhanced influx of circulating CXCR3 and CCR6-expressing effector Th1 and Th17 lymphocytes
in the DSS-injured colons [40,41]. Furthermore, IL-1β:IL-1R signaling activates IL-1β converting
enzyme (ICE) in colon macrophages and promotes de novo synthesis and release of IL-1β, resulting
in the creation of “inflammatory cytokine loop” in DSS-injured colons, which finally results in the
development of severe acute colitis [42]. On the contrary, decreased production of IL-1β in LPS-activated
colon macrophages and consequent low concentration of IL-1β results in sub-optimal activation of
IL-1R/MyD88 signaling pathway in macrophages, neutrophils, and DCs, but facilitate the production
of granulocyte-macrophage colony-stimulating factor (GM-CSF) in type 3 innate lymphoid cells
(ILC3) [43]. Accordingly, low levels of IL-1β and elevated concentration of GM-CSF induce generation
of immunosuppressive, M2 phenotype in colon-infiltrated macrophages during the induction phase of
DSS-induced inflammation [43]. While IL-1β regulates the onset of DSS-induced colitis, neutralization
of IL-1β:IL-1R signaling in colon-infiltrating macrophages failed to show beneficial effects in mice with
chronic DSS-induced colitis, indicating that other immunomodulatory molecules regulate macrophage
polarization and function during the progression of colon inflammation [44].
In line with these findings are our results that showed that Gal-3 was required for optimal
NLRP3-dependent production of IL-1β in colonic macrophages during the development of acute
colitis [9]. In an analogy, herewith we showed that during the induction phase of DSS-induced colitis
Gal-3 deficient macrophages were not able to optimally produce IL-1β upon TLR4:LPS stimulation
which led to their polarization towards immunosuppressive M2 phenotype (Figure 1L). However,
completely opposite findings were observed during the progression of DSS-induced colon inflammation.
Significantly lower number of IL-10-, IL-4- and TGF-β-producing M2 macrophages infiltrated colons of
DSS-treated Gal-3−/− animals 28 days after initial administration of DSS, which resulted in aggravation
of DSS-induced colitis (Figure 2I). It is well known that soluble Gal-3 is required for the maintenance
of M2 macrophage subpopulation in inflamed tissues [45]. M2 macrophages secrete Gal-3, which
promotes alternative activation of neighboring macrophages and creates “autocrine loop” that results
in alleviation of on-going inflammation [45]. Accordingly, we assume that during the induction
phase of colitis, total number of M2 macrophages was higher in colons of Gal-3−/− mice due to the
reduced activation of NLRP3/IL-1β pathway. However, during the progression of colitis, due to the
deficiency of soluble Gal-3, polarization of colonic macrophages in M2 phenotype was prevented
and pool of alternatively activated macrophages in the colons of DSS-treated Gal-3−/− mice could not
be maintained.
Alternatively, activated M2 macrophages suppress on-going colon inflammation either directly,
through the production of anti-inflammatory TGF-β and IL-10, or indirectly, by promoting expansion
of immunosuppressive Tregs in the DSS-injured colons [46]. Accordingly, lower number of TGF-β
and IL-10-producing colonic M2 macrophages in the colons of Gal-3−/− mice at day 28 (Figure 2I)
corresponded to the reduced presence of colon-infiltrated Tregs (Figure 3D-E). Tregs are considered
as the main immunosuppressive cells in UC due to their capacity to suppress detrimental Th1 and
Th17 cell-driven colon inflammation [47]. Th1 cells, through the production of IFN-γ, reinforce
the pro-inflammatory phenotype in colonic macrophages, whereas Th17 cells, in a IL-17-dependent
manner, promote activation of colon-infiltrated neutrophils, contributing to crypt abscess formation
and aggravation of UC [46]. In line with these findings, aggravated colitis observed in Gal-3−/− mice
four weeks after DSS administration was characterized by the increased presence of colon-infiltrating
Th1 and Th17 cells (Figure 3B,C).
T cell driven inflammation in the gut and polarization of naïve T cells in Tregs or in inflammatory
Th1/Th17 cells is regulated by cytokine production of colon-infiltrating DCs [48]. Cellular make-up
Cells 2019, 8, 709 18 of 24
of the colons revealed significantly higher number of CD40, CD80, and CD86-expressing DCs which
produce Th1 (IL-12) and Th17-related (IL-6, IL-23) cytokines (Figure 4B-G). In contrast, genetic deletion
of Gal-3 resulted in the significantly lower number of regulatory, IL-10 and KYN-producing DCs
(Figures 4H and 5B).
Several recently published experimental and clinical studies indicated important protective role of
tryptophan (TRP) and its metabolite KYN in attenuation of colon inflammation [49–52]. Administration
of TRP significantly alleviated DSS-induced colon injury in mice while removing TRP from the diet
remarkably increased susceptibility to experimental colitis [51,52]. These findings have been recently
confirmed in clinical settings by Nikolaus and colleagues who observed significantly lower serum
levels of TRP in UC patients compared to the healthy controls [49].
IDO-1/KYN pathway comprises most of TRP metabolism in the inflamed gut [53]. Accordingly,
IDO-1-expressing cells regulate TRP-dependent effects in the gastrointestinal tract, including the
control of host-microbiota interactions, regeneration of DSS-injured epithelial cells, and alleviation
of detrimental immune response in the gut [54,55]. High expression of IDO-1 was noticed in the
epithelial cells flanking ulcers or bordering crypt abscesses within the inflamed mucosa of UC
patients [56]. The highest expression of IDO-1 was observed at the margin of mucosal erosions and in
the reparative ulcer-associated cell lineage suggesting important role of IDO-1 in mucosal healing and
regeneration of injured epithelial cells [56]. Additionally, an enhanced IDO-1 activity has been noticed in
endothelial cells, fibroblasts, as well as immune cells with immunosuppressive and anti-inflammatory
properties including CD8α+CD16+, CD8α+CD56+, CD8α+CD80+, CD8α+CD123+ large granular
cells, and CD123+plasmacytoid DCs [57]. Through the increased IDO-1 activity colon-infiltrated
immunosuppressive cells maintains immune tolerance and attenuates on-going inflammation in the
gut. Decreased number of IDO-1-expressing DCs resulted in tolerance loss and aggravation of colon
injury and inflammation in UC patients [57].
Several lines of evidence indicated that the cross-talk between IDO-1-expressing DCs and Tregs
was crucially important for the maintenance of immune tolerance and regeneration of injured epithelial
cells in the gut [17,35,54]. Colon-infiltrated regulatory DCs, in IDO-1/KYN-dependent manner, promote
expression of Treg lineage-defining transcription factor FoxP3 in naive CD4+T cells enabling generation
of immunosuppressive CD4+FoxP3+Tregs [35]. During TCR-mediated activation of resting Tregs,
signals via the protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR) pathways
can destabilize the immunoregulatory phenotype of Tregs and cause their reprogramming into
a pro-inflammatory (“ex-Tregs”) phenotype, characterized by enhanced production of IFN-γ and
IL-17 [54,58,59]. Importantly, colon-infiltrating regulatory DCs may prevent transdifferentiation of
Tregs in Th1 or Th17 cells [54,58,59]. Through the increased IDO-1 activity, regulatory DCs reduce
concentration of TRP in the inflamed microenvironment of the gut. The low level of TRP, in turn,
activates general control nonderepressible 2 (GCN2) kinase, which inhibits Akt/mTORC2 signaling in
Tregs and prevents their transdifferentiation in Th1 or Th17 cells [54,60]. In line with these findings,
herewith, we demonstrated that Gal-3 is required for IDO-1/KYN-dependent cross-talk between DCs
and Tregs in the inflamed gut as well as for IDO-1/KYN-mediated maintainance of Treg phenotype
and function. Genetic deletion of Gal-3 significantly reduced capacity of regulatory DCs to produce
KYN (Figure 5B), which resulted in the reduced presence of colon-infiltrating Tregs in DSS-treated
Gal-3−/− mice (Figure 3E).
There was strong positive correlation between the expression of Gal-3 and expression of TLR-4
in colon-infiltrating DCs (Figure 5A). Interestingly, TRL-4 priming, significantly increased KYN
production in DCs (Figure 5B). It is well known that LPS-induced activation of TLR-4 induces
activation of IDO-1 and results in enhanced production of immunosuppressive KYN in regulatory
DCs [34]. Since Gal-3 acts as a ligand for TLR-4 that enables sustained TLR-4 signaling [61], genetic
deletion, as well as pharmacological inhibition of Gal-3 significantly reduced capacity of TLR-4
primed DCs to produce immunosuppressive KYN (Figure 5B). TLR-4 priming results in increased
activation of Phosphoinositide 3-kinase (PI3K)/Akt signaling pathway in DCs leading to the enhanced
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production of immunosuppressive cytokines [62]. Activated TLR-4 recruits PI3K that converts
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3
enables activation of Akt. Activated Akt, on turn, inactivates Glycogen Synthase Kinase 3 (GSK3)
and promotes nuclear accumulation of cAMP Response Element-Binding Protein (CREB) which
displaces NF-κB p65 from the co-activator of transcription (CREB binding protein (CBP)). Accordingly,
enhanced transcriptional activity of CREB leads to the reduced transcriptional activity of NF-κB
p65 and results in increased production of immunosuppressive cytokines and decreased production
of pro-inflammatory cytokines in TLR-4-primed DCs [62]. Since Gal-3 stimulates activation of
PI3K/Akt signaling pathway in macrophages and promotes their conversion in M2 immunosuppressive
phenotype in PI3K/Akt-dependent manner [45], we assume that Gal-3:TLR-4-dependent induction of
tolerogenic phenotype in colon infiltrated DCs was a consequence of an increased PI3K/Akt activity.
Gal-3 deficiency abrogated capacity of DCs to prevent transdifferentiation of Tregs in inflammatory
Th1 or Th17 cells in IDO-1/KYN dependent manner (Figure 5C). Additionally, Tregs generated by TLR-4
primed Gal-3−/−DCs were not able to optimally suppress production of inflammatory cytokines in Th1
and Th17, confirming the importance of Gal-3:TLR-4 interaction for DC-driven regulation of cross-talk
between Tregs and effector T cells (Figure 5D). Since LPS preconditioning enhances anti-inflammatory
properties of DCs [34], adoptive transfer of TLR-4-primed WTDCs attenuated DSS-induced colitis
by increasing serum levels of IL-10 and KYN and by inducing expansion of colon-infiltrating,
IL-10-producing Tregs which was accompanied by alleviated Th1 and Th17 cell-driven inflammation
(Figure 6). Importantly, this phenomenon was not observed after passive transfer of LPS-primed
Gal-3−/−DCs, indicating a crucial importance of Gal-3 for TLR-4-dependent activation of IDO-1/KYN
pathway in DCs and for DCs-induced expansion of colon-infiltrated Tregs during the alleviation of
DSS-induced colitis.
In similar manner as it was observed in animal model, patients’ data indicated important
protective role of Gal-3 in alleviation of UC. An increased serum and fecal levels of Gal-3 correlated
with concentration of KYN (Figures 8A and 9E) and IL-10 (Figures 8D and 9G) indicating that elevation
in Gal-3 reflects overproduction of immunosuppressive cytokines in UC patients. Since up-regulation
of KYN and IL-10 in serum and tissue samples of UC patients attenuate detrimental immune response
in the gut, alleviate colon inflammation and promote mucosal healing of injured epithelial cells [17],
elevated concentration of serum, and fecal Gal-3 may be considered as an additional immunoregulatory
mechanism that contributes to the regeneration of the injured gut.
Accordingly, concentration of Gal-3 in serum and stool samples of UC patients negatively
correlated with clinical, endoscopic and histological parameters of disease severity (Figure 7C–F). ROC
analysis revealed that measurement of serum and fecal levels of Gal-3 (Figures 7G and 9D) could
be used as a new diagnostic tool for predicting aggravation of UC, which may complement FC for
monitoring attenuation of colon injury in UC patients.
In line with our results, several research groups indicated that serum levels and colon tissue
expression of Gal-3 might predict severity and progression of UC [8,13,63]. Frolova and colleagues
noticed elevated concentrations of Gal-3 in serum samples of UC patients with active disease [8],
while Papa Gobbi and associates revealed dysregulated expression of galectins (Gal-1,-3,-4 and -9) in
inflamed colon tissues of IBD patients compared with non-inflamed colon tissue samples of patients
suffering from non-inflammatory colon diseases, suggesting that galectin-specific signature in the
gut may be used for the diagnosis of Crohn’s disease and UC [13]. Although Papa Gobbi and
colleagues managed to discriminate IBD from other intestinal inflammatory conditions by using linear
discriminate integrative analysis of galectins, galectin profiling could not distinguish Crohn’s disease
and UC-related pathological changes in the gut [13]. By using immunohistochemical analysis, Block
and colleagues revealed that Gal-3 is expressed on colon-infiltrated immune cells of UC patients,
but its expression on gut epithelial cells did not correlate with disease severity and could not be used
for monitoring disease progression [63]. It has to be noted that expression of Gal-3 in serum and
colon tissue samples of UC patients is dependent on individual characteristics of UC patients [64],
Cells 2019, 8, 709 20 of 24
which might be the reason why Cibor and coworkers did not observe a significant difference in serum
levels of Gal-3 between UC patients with active and inactive disease [64]. Therefore, heterogeneity of
demographic and clinical characteristics of UC patients might affect potential utility of using Gal-3 as a
biomarker for monitoring UC progression and have to be considered when serum concentration and
expression of Gal-3 in colon tissue are analyzed.
In summing up, the main mechanism by which Gal-3 regulates immunosuppressive capacity
of regulatory DCs in the gut is relied on the TLR-4-dependent activation of IDO-1/KYN pathway
and consequent expansion of colon-infiltrated Tregs which suppress Th1 and Th17 cell-driven colon
inflammation (Figure 10). Since serum and fecal levels of Gal-3 inversely reflect disease severity,
we proposed that Gal-3 level may serve as a valuable biomarker for monitoring disease progression in
UC patients.
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